Nitin Jain, M.D., is a Professor of Medicine in the Department of Leukemia at The University of Texas MD Anderson Cancer Center (MDACC) in Houston, Texas, USA. He earned his medical degree from the All India Institute of Medical Sciences (AIIMS), New Delhi, India in 2002. He completed Internal Medicine residency at the Medical College of Wisconsin, Milwaukee. He then completed clinical fellowship in Leukemia at MDACC followed by a Leukemia research fellowship at Memorial Sloan-Kettering Cancer Center. He then pursued fellowship in Hematology/Oncology at The University of Chicago. He joined as a faculty in the Department of Leukemia at MDACC in July 2012. Dr. Jain treats patients with acute and chronic leukemias with focus of patients with chronic lymphocytic leukemia (CLL) and acute lymphoblastic leukemia (ALL). Since 2021, he has served as Director, Leukemia CAR-T Program within the Department of Leukemia, MDACC. Dr. Jain is Principal Investigator of several investigator-initiated phase I-II clinical trials. The trial combining ibrutinib and venetoclax was published in New England Journal of Medicine in 2019. He has published papers in prominent journals including NEJM, Lancet, JAMA Oncology, Journal of Clinical Oncology, Blood, Clinical Cancer Research, Cancer, Leukemia & Lymphoma, and others. He has served as faculty on American Society of Hematology CRTI workshop from 2017-2019. He is recipient of Sabin Family Foundation Award in 2018. In 2020, he received MD Anderson Faculty Scholar award. In 2022, he received Leukemia and Lymphoma Society Career Development Program Award as well as Translational Research Program (TRP) award.